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Abstract
Objectives:	 Diffusion	 tensor	 imaging	 (DTI)	 is	 sensitive	 technique	 to	 detect	 wide‐
spread	changes	in	water	diffusivity	in	the	normal‐appearing	white	matter	(NAWM)	
that appears unaffected in conventional magnetic resonance imaging. We aimed to 
investigate	 the	prognostic	 value	 and	 stability	of	DTI	 indices	 in	 the	NAWM	of	 the	
brain in an assessment of disability progression in patients with a relapsing‐onset 
multiple	sclerosis	(MS).
Methods:	Forty‐six	MS	patients	were	studied	for	DTI	indices	(fractional	anisotropy	
(FA),	mean	diffusivity	(MD),	radial	(RD),	and	axial	(AD)	diffusivity)	in	the	NAWM	of	the	
corpus	 callosum	 (CC)	 and	 the	 internal	 capsule	 at	baseline	 and	at	1	year	 after.	DTI	
analysis	for	10	healthy	controls	was	also	performed	at	baseline.	Simultaneously,	focal	
brain lesion volume and atrophy measurements were done at baseline for MS pa‐
tients.	Associations	between	DTI	 indices,	volumetric	measurements,	and	disability	
progression over 4 years were studied by multivariate logistic regression analysis.
Results:	At	baseline,	most	DTI	metrics	differed	 significantly	between	MS	patients	
and	healthy	controls.	There	was	tendency	for	associations	between	baseline	DTI	in‐
dices	 in	 the	CC	 and	 disability	 progression	 (p	<	0.05).	 Changes	 in	DTI	 indices	 over	
1	year	were	observed	only	in	the	CC	(p	<	0.008),	and	those	changes	were	not	found	
to predict clinical worsening over 4 years. Clear‐cut association with disability pro‐
gression was not detected for baseline volumetric measurements.
Conclusion:	Aberrant	diffusivity	measures	in	the	NAWM	of	the	CC	may	provide	ad‐
ditional information for individual disability progression over 4 years in MS with the 
relapsing‐onset	disease.	CC	may	be	a	good	target	for	DTI	measurements	in	monitor‐
ing	disease	activity	in	MS,	and	more	studies	are	needed	to	assess	the	related	prog‐
nostic potential.
K E Y W O R D S
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1  | INTRODUC TION
In	 multiple	 sclerosis	 (MS),	 demyelination	 and	 axonal	 injury	 in	 the	
central nervous system are responsible for neurological disability. 
Conventional	magnetic	resonance	imaging	(MRI)	detecting	T1	and	T2	
focal	brain	lesions	is	not	specific	to	the	underlying	pathology,	and	it	
lacks sensitivity to the microstructural diffuse damage in the normal‐
appearing	white	matter	 (NAWM)	 (Filippi,	Absinta,	&	Rocca,	2013).	
Conventional	MRI	markers	 correlate	 only	moderately	with	 clinical	
disability	(Tintore	et	al.,	2015),	and	their	prognostic	value	in	the	as‐
sessment	of	disability	progression	 in	definite	MS	 is	 limited	 (Filippi	
et	al.,	2013).	Consequently,	brain	atrophy	that	has	been	related	to	
long‐term	disability	 in	MS	 (De	 Stefano	 et	 al.,	 2016)	 expresses	 the	
underlying pathological processes only nonspecifically. Confounding 
factors,	such	as	disease‐modifying	therapies	and	causes	unrelated	to	
MS,	complicate	interpretation	of	MRI	markers	and	atrophy	in	clinical	
practice	(Kaunzner	&	Gauthier,	2017;	Wattjes	et	al.,	2015).
Diffusion	 tensor	 imaging	 (DTI)	 quantifies	 the	 magnitude	 and	
direction	 of	 water	 diffusion,	 and	 it	 is	 sensitive	 to	 diffuse	 micro‐
structural abnormalities in the brain that appears unaffected on con‐
ventional	MRIs	(Rovaris	et	al.,	2005).	DTI‐derived	metrics,	including	
fractional	 anisotropy	 (FA),	 mean	 diffusivity	 (MD),	 radial	 (RD),	 and	
axial	(AD)	diffusivities,	seem	to	provide	a	better	specificity	to	demy‐
elination	and	axonal	injury	than	conventional	MRIs	(Sun	et	al.,	2006).	
Increased	MD	and	 decreased	 FA	 in	 the	NAWM	of	 different	 brain	
regions,	including	the	corpus	callosum	(CC),	have	been	typically	de‐
tected	 in	MS	 (Banaszek,	Bladowska,	Pokryszko‐Dragan,	Podemski,	
&	Sasiadek,	2015;	Preziosa	et	al.,	2011;	Sigal,	Shmuel,	Mark,	Gil,	&	
Anat,	2012).	However,	inconsistent	results	regarding	the	correlation	
between	disability	and	DTI	indices	in	the	CC	and	the	pyramidal	tract	
have been reported in cross‐sectional studies using different meth‐
ods	of	DTI	analysis	and	clinical	scales	of	disability	(Lin,	Yu,	Jiang,	Li,	
&	Chan,	2007;	Llufriu	et	 al.,	2012;	Pokryszko‐Dragan	et	al.,	2018;	
Roosendaal	et	al.,	2009;	Tortorella	et	al.,	2014).	The	correlation	be‐
tween	RD	and	secondary	progression	in	MS	has	been	observed	in	a	
50‐year	clinical	follow‐up	study	indicating	the	potential	role	of	DTI	in	
the	prediction	of	outcomes	in	MS	(Andersen	et	al.,	2018).
Previously,	decreased	FA	and	increased	RD	mostly	in	the	CC	of	
MS	were	 observed	 in	 a	 2‐year	 longitudinal	 study	 (Harrison	 et	 al.,	
2011).	 In	 contrast,	 no	 changes	 in	diffusivity	were	observed	 in	 the	
NAWM	of	MS	over	2–4	years	(Ontaneda	et	al.,	2017;	Rashid	et	al.,	
2008).	Moreover,	few	studies	with	a	short	(1–2	years)	follow‐up	have	
applied	a	regional	and	whole‐brain	DTI	analysis	to	longitudinal	mea‐
surements of diffusivity aiming to evaluate the prognostic value of 
DTI	in	the	assessment	of	disability	progression	in	MS	(Rashid	et	al.,	
2008;	Samann	et	al.,	2012;	Schmierer	et	al.,	2004).	In	one	of	these	
studies,	the	increase	of	MD	in	the	white	matter	of	frontal	lobe	over	
1 year was associated with clinical impairment in primary‐progres‐
sive	MS	 (Schmierer	 et	 al.,	 2004),	 while	 in	 another	 study,	 in	 early	
relapsing‐remitting	MS,	no	diffusivity	changes	were	detected	over	
2	years	(Rashid	et	al.,	2008).
The	 investigation	 of	 the	 prognostic	 value	 of	DTI	 in	 this	 cross‐
sectional and 4‐year longitudinal study aims to assess white matter 
diffusion change and its stability in the relapsing‐onset MS cohort 
considering the variable rate of disease progression.
2  | MATERIAL S AND METHODS
The study was approved by the local ethics committee in the 
Hospital	District	 of	 Pirkanmaa	 (R05157).	 All	 subjects	 provided	 in‐
formed written consent.
2.1 | Subjects
In	total,	56	individuals,	46	patients	with	relapsing‐onset	MS,	and	10	
healthy	 subjects	were	enrolled	 in	 this	4‐year	 follow‐up	 study	 (be‐
tween	2006	and	2012)	at	the	Tampere	University	Hospital,	Finland.	
The	MS	diagnosis	was	based	on	the	revised	McDonald	criteria	from	
2005	(Polman	et	al.,	2005)	and	the	disease	course	classification	on	
Lublin	and	Reingold	criteria	(Lublin	et	al.,	2014).	The	inclusion	crite‐
ria	were	a	diagnosis	of	relapsing‐remitting	MS	(RRMS)	or	secondary‐
progressive	MS	(SPMS),	no	steroid	treatment	at	least	8	weeks	before	
clinical	 and	 radiological	 assessments,	 and	 an	 Expanded	 Disability	
Status	Scale	(EDSS)	score	both	at	the	study	entry	and	after	4	years.	
Healthy	subjects	consisted	of	five	females	and	five	males,	and	the	
mean	age	of	the	subjects	was	39.7	years	(range	26–61).	Healthy	sub‐
jects were recruited from the hospital staff or their relatives with no 
history of neurological or psychiatric illness.
During	the	follow‐up,	MS	patients	underwent	a	clinical	examina‐
tion	by	the	same	neurologist	at	baseline	and	annually	for	4	years	(in	
total	five	examinations).	Clinical	progression	was	determined	as	the	
difference	between	the	baseline	EDSS	and	EDSS	4	years	after	the	
baseline. Progression of disability during the follow‐up was defined 
as	an	EDSS	score	increase	≥1.0	when	the	baseline	EDSS	was	<6.0	or	
an	increase	of	EDSS	≥	0.5	when	the	baseline	EDSS	≥	6.0,	and	these	
subjects	were	assigned	to	a	progression	group	(Rovaris	et	al.,	2003).	
All	the	other	patients	were	included	in	the	stable	group.
2.2 | MR imaging acquisition
MRI	volumetry	included	T1	and	FLAIR	brain	lesion	volume	and	brain	
atrophy	 measurements,	 and	 it	 was	 carried	 out	 at	 baseline	 for	 42	
MS	patients.	DTI	in	46	cases	was	performed	at	baseline	and	1	year	
after	the	baseline	visit.	Healthy	controls	were	assessed	with	DTI	at	
baseline.
The	patients	underwent	MRI	on	 the	 same	day	as	a	 clinical	ex‐
amination. The patients and controls underwent a whole‐brain 
imaging	 by	 using	 a	 1.5‐Tesla	MR	 scanner	 (Magnetom	 Avanto	 SQ,	
Siemens	Medical	Solutions,	Erlangen,	Germany),	and	the	MRI	acqui‐
sition and protocol were as follows: T1‐weighted header followed 
by	an	axial	three‐dimensional	(3D)	T1‐weighted	magnetization	pre‐
pared	 rapid	 gradient	 echo	 (MPRAGE),	 3D	T2‐weighted	 turbo	 spin	
echo,	 fluid‐attenuated	 inversion	 recovery	 (FLAIR),	 T1‐weighted	
spin	 echo	 with	 magnetization	 transfer	 contrasts,	 multidirectional	
diffusion‐weighted	echo‐planar	 imaging,	and	gadolinium‐enhanced	
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T1‐weighted	MPRAGE	when	needed.	The	DTI	protocol	consisted	of	
a single‐shot spin‐echo‐based echo‐planar diffusion‐weighted imag‐
ing	with	three	averages	and	12	gradient	encoding	directions,	with	b	
values	of	0	and	1,000	s/mm2. The imaging parameters are presented 
in Table 1.
2.3 | MR imaging postprocessing
The	DTI	 data	were	 analyzed	with	 commercial	Neuro	3D	 software	
(Siemens	 Healthcare,	 Malvern,	 USA)	 at	 an	 offline	 workstation.	
Multidirectional diffusion data were assessed visually for the pres‐
ence of distortions and artifacts. There were no significant eddy cur‐
rent distortions due to the diffusion gradients. Six freehand regions 
of	 interest	 (ROI)	 of	 approximately	 26–48	mm2	 (depending	 on	 the	
anatomical	 region)	were	positioned	on	 the	 left	 and	 right	posterior	
limbs	of	the	 internal	capsule	 (IC),	CC	genu,	 left	and	right	CC	body,	
and	CC	splenium	(Figure	1).	The	ROIs	were	manually	placed	exactly	
the same way at both time points on axial images of the color‐coded 
FA	maps	and	were	automatically	transferred	on	the	MD,	eigenval‐
ues,	and	non‐diffusion‐weighted	b0	maps.	The	ROIs	were	centered	
on	 the	 anatomical	 structure	 in	 the	most	 homogeneous	 area,	with	
guidance from conventional T2 images to exclude focal lesions from 
the	ROI	and	partial	volume	effect	from	border	areas.	The	size	of	ROI	
was	reduced	 if	a	focal	 lesion	was	 identified	 in	the	ROI.	The	differ‐
ence	in	ROI	size	between	the	baseline	and	1‐year	follow‐up	was	very	
small,	<9%	(range	1.8%–8.8%)	in	all	ROIs.	The	values	of	the	following	
DTI	parameters	were	obtained:	FA,	MD,	AD,	and	RD.
The	whole	brain	volume	of	the	T1	hypointense,	FLAIR	hyperin‐
tense	 lesions,	 and	brain	parenchymal	 fraction	 (BPF)	were	 assessed	
blindly	using	the	semi‐automatic	segmentation	software	Anatomatic™	
2.23	(Heinonen	et	al.,	1998)	by	the	same	reader.	BPF	was	defined	as	
a ratio of brain parenchymal volume to the total volume within the 
brain	surface	contour	(Rudick,	Fisher,	Lee,	Simon,	&	Jacobs,	1999).
2.4 | Statistical analysis
Means and standard deviations were given for normally distributed 
variables and medians and ranges for skewed distributed data. For 
the	demographic	and	volumetric	data,	groups	were	compared	using	
independent sample t tests for normally distributed continuous vari‐
ables	and	Mann–Whitney	U tests for skewed distributed continuous 
variables. Spearman's rank correlations were determined for correla‐
tions	between	clinical	and	MRI	parameters.	The	Wilcoxon	test	was	
used	 to	perform	comparisons	between	DTI	values	at	baseline	and	
1	year.	To	 investigate	association	between	DTI	metrics,	volumetric	
measurements,	 and	disability	progression	over	4	years,	 a	 series	of	
logistic regression models were created. The presence or absence 
of disability progression was used as a dependent variable in all 
models.	 In	 logistic	 regression	Model	1,	 the	age	and	 time	 from	 the	
onset	(first	symptoms)	to	baseline	were	set	as	covariates.	In	Model	
2,	 the	covariates	were	as	follows:	sex,	disease	duration	 (time	from	
MS	diagnosis	to	baseline),	baseline	EDSS,	number	of	relapses	up	to	
3	years	preceding	the	baseline,	immunomodulatory	medication	sta‐
tus,	and	volumetric	measurements	 (T1/FLAIR	 lesion	volume,	BPF).	
A	 resulting	 odds	 ratio	 (OR)	 is	 given	with	 95%	 confidence	 interval	
(CI),	 and	 the	p‐value	<0.05	was	considered	statistically	 significant.	
The Bonferroni‐corrected p‐values	 for	 six	 comparisons	 (p	<	0.008)	
were	also	investigated	in	the	analyses	concerning	DTI.	A	statistical	
analysis was performed using SPSS Statistics for Windows version 
22	(IBM	Corp.,	Armonk,	NY,	USA).
3  | RESULTS
3.1 | Clinical and radiological assessment at baseline 
and over the follow‐up
In	total,	22	of	46	(48%)	patients	showed	disability	progression	over	
4	years.	The	mean	age	of	patients	at	baseline	was	39.6	years	(range	
18–61).	 The	 demographic	 and	 clinical	 characteristics	 are	 summa‐
rized	in	Table	2.	Seven	patients	had	one	demyelinating	plaque	in	the	
IC,	four	patients	had	one	demyelinating	plaque	in	the	CC,	and	one	
patient	had	several	plaques	in	the	CC.
Incidental	findings	in	the	brain	white	matter	were	found	in	four	
healthy subjects from control group; three subjects had one to two 
punctate	 white	 matter	 hyperintensities,	 one	 subject	 had	 several	
punctate	white	matter	 hyperintensities,	 and	 none	 of	 healthy	 sub‐
jects presented clinical signs of demyelinating disease.
In	MS,	compared	to	healthy	subjects,	the	strongest	differences	
(p	<	0.001)	were	 found	 in	 the	CC	for	FA,	MD,	and	RD	 (Supporting	
Information	Figure	S1).
The	 FLAIR	 lesion	 volumes	 were	 significantly	 higher	 (p	<	0.05)	
in the disability progression group compared to the stable disabil‐
ity	group	(Table	2).	No	significant	correlations	were	found	between	
baseline	DTI	and	age,	disease	duration,	baseline	EDSS,	and	number	
of	relapses	before	baseline	(data	not	shown).
At	 baseline,	 significant	 correlations	 (p	<	0.008,	 r	>	0.4)	 were	
found	between	MRI	volumetric	measurements	and	DTI	indices.	The	
strongest correlations were found in the CC genu between the T1 
brain	 lesion	 volume	 and	 FA	 (p	=	0.001,	 r	=	−0.48),	MD	 (p	<	0.001,	
r	=	0.52),	 RD	 (p	<	0.001,	 r	=	0.52)	 and	 between	 FLAIR	 lesion	 vol‐
ume	and	FA	 (p	<	0.001,	 r	=	−0.6),	MD	 (p	<	0.001,	 r	=	0.54),	and	RD	
TA B L E  1   Imaging	parameters
Axial T1WI Axial FLAIR Axial DTI
Slice thickness 
(mm)
0.9 5 5
Interslice	gap	(mm) 0 0 1.5
Field	of	view	(mm) 230 × 230 230 × 230 230 × 230
Matrix 256	×	256 256	×	256 128 × 128
Echo	time	(ms) 4.2 100 96
Repetition time 
(ms)
1,160 8,500 3,500
Inversion	time	(ms) 600 2,500
Note.	 DTI:	 diffusion	 tensor	 imaging;	 FLAIR:	 fluid‐attenuated	 inversion	
recovery;	T1WI:	T1‐weighted	imaging.
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(p	<	0.001,	 r	=	0.6).	Regarding	brain	atrophy,	 the	strongest	correla‐
tions	were	found	between	BPF	and	RD	(p	=	0.002,	r	=	−0.46)	in	the	
right	 CC	 body,	 RD	 (p	=	0.007,	 r	=	−0.41)	 in	 the	 left	 CC	 body,	MD	
(p	=	0.004,	 r	=	−0.44)	and	AD	 (p	=	0.001,	 r	=	−0.49)	 in	 the	 right	 IC,	
and	MD	 (p	<	0.001,	 r	=	−0.53)	and	AD	 (p	=	0.002,	 r	=	−0.47)	 in	 the	
left	IC	(Supporting	Information	Table	S1).
During	the	1‐year	follow‐up,	FA	significantly	(p	<	0.05)	increased	
in	4/6	ROIs,	and	RD	decreased	in	4/6	ROIs	(CC	genu,	body,	and	the	
CC	splenium).	AD	showed	a	significant	increase	in	3/6	ROIs	(the	CC	
genu,	CC	body).	The	 results	 remained	significant	except	 for	RD	 in	
the	CC	genu	and	AD	in	left	CC	body	after	the	Bonferroni	corrections	
(p	<	0.008).	In	the	IC,	the	changes	were	nonsignificant	(Table	3).
No	group	differences	existed	regarding	DTI	change	over	1	year	
in	any	ROIs	between	disability	progression	and	stable	groups	(data	
not	shown).
To	assess	the	intra‐observer	repeatability	of	DTI	measurements,	
the	 intraclass	 correlations	 (ICCs)	 were	 calculated	 for	 20	 patients.	
The	same	observer	(U.H.)	repeated	the	measurements	for	the	same	
scans	with	a	time	interval	of	approximately	3	months.	In	all	ROIs,	the	
ICCs	were	good	and	excellent	and	were	0.77–0.98	(mean	0.91)	for	
FA,	0.75–0.96	(mean	0.84)	for	MD,	0.64–0.93	(mean	0.85)	for	AD,	
and	0.85–0.95	(mean	0.91)	for	RD.
3.2 | Association between MRI markers and 
disability progression
In	logistic	regression	Model	1	with	covariates	of	age	and	time	from	
the	onset	to	baseline	(Table	4),	a	lower	baseline	FA	and	higher	RD	in	
the	CC	genu,	right	CC	body,	and	the	CC	splenium	were	associated	
with	 disability	 progression	 (p	˂	0.05).	Moreover,	 a	 higher	 baseline	
MD	 in	 the	 right	CC	body	 and	 higher	MD	and	AD	 in	 the	CC	 sple‐
nium were associated with disability progression. The results did not 
remain significant after the Bonferroni corrections. There were no 
significant	associations	between	baseline	DTI	indices	in	the	IC	and	
disability progression over the follow‐up. The age and symptom time 
had	no	effect	in	any	of	the	analyzed	ROIs.
In	Model	2,	which	contained	baseline	EDSS	and	relapse	number	
before	baseline,	an	association	between	DTI	and	disability	progres‐
sion	disappeared	in	the	CC	genu,	body,	and	the	splenium	regrading	
several	diffusivity	parameters;	however,	none	of	these	explanatory	
variables	 reached	 statistical	 significance	 (Supporting	 Information	
Tables	 S2	 and	 S3).	 Medication,	 disease	 duration,	 and	 sex	 had	 no	
effect	 on	 disability	 progression	 (data	 not	 shown).	 T1,	 FLAIR,	 and	
BPF	 were	 not	 explanatory	 for	 disability	 progression	 (Supporting	
Information	 Table	 S4).	 However,	 the	 association	 between	 disabil‐
ity	progression	and	DTI	disappeared	in	the	CC	genu,	and	statistical	
power	 slightly	 decreased	 in	 the	other	CC	 areas	 in	 the	models,	 in‐
cluding	FLAIR	lesion	volume	and	BPF.	The	T1	lesion	volume	had	no	
effect	in	any	regression	model	(data	not	shown).
DTI	 change	over	1	year	did	not	 relate	 to	disability	progression	
over	4	years	in	any	ROIs	(data	not	shown).
4  | DISCUSSION
The prognostic assessment of clinical disability accumulation by 
using	conventional	MRI	is	still	suboptimal	(Filippi	et	al.,	2013),	where	
additional challenges concern the individual and heterogenous dis‐
ability	 progression.	 In	 the	 present	 study,	 the	 relapsing‐onset	 MS	
patient	cohort	showed	altered	DTI	indices	at	baseline	compared	to	
healthy	controls,	especially	in	the	CC	and	to	a	lesser	degree	in	the	
IC.	The	anatomical	 location	of	 the	observed	differences	may	 indi‐
cate	that	DTI	is	sensitive	to	microstructural	abnormalities	occurring	
in	the	NAWM	tracts	responsible	for	cognitive	and	locomotor	func‐
tions.	Our	finding	corroborates	other	reports	showing	that	AD	is	less	
affected	when	compared	to	RD	in	the	CC	and	the	pyramidal	tract,	
F I G U R E  1  Freehand	ROI	placement	on	the	color‐coded	fractional	anisotropy	axial	maps.	(1)	Genu	of	the	corpus	callosum	(size	of	ROI	
means	26	mm2,	range	13–71),	(2)	posterior	limb	of	the	internal	capsule	(48	mm2,	13–81),	(3)	splenium	of	the	corpus	callosum	(32	mm2,	
13–81),	(4)	body	of	the	corpus	callosum	(26	mm2,	19–84).	Pixel	size	1.8	×	1.8	mm
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including	IC	(Henry,	Oh,	Nelson,	&	Pelletier,	2003;	Lin	et	al.,	2007;	
Roosendaal	et	al.,	2009).
In	the	NAWM	of	MS,	FA	is	typically	decreased,	whereas	MD	is	
increased,	expressing	the	 loss	of	white	matter	tracts	directionality	
and	the	increase	in	overall	water	diffusivity,	respectively	(Alexander,	
Lee,	Lazar,	&	Field,	2007).	Increased	RD,	a	measure	of	perpendicu‐
lar	diffusivity	to	the	fibers,	 is	usually	 linked	to	demyelination	 (Fink	
et	 al.,	 2010).	Diffusion	parallel	 to	 the	 fibers,	 that	 is,	AD,	 a	marker	
of	axonal	integrity,	is	typically	decreased	and	correlates	clearly	with	
axonal	damage	at	the	early	stages	of	MS.	At	the	chronic	stage	of	MS,	
AD	may	conversely	increase,	representing	the	confounding	effect	of	
reparative	processes,	such	as	gliosis	and	cellular	 infiltration	 (Aung,	
Mar,	&	Benzinger,	2013).	 In	 this	context,	 the	nonsignificant	differ‐
ence between healthy controls and MS patients in our study may 
result	from	different	directions	of	change	in	AD	representing	com‐
peting pathological processes at different progression stages in MS. 
The	correlation	between	baseline	brain	lesion	volume,	brain	atrophy,	
and	DTI	measurements	 in	 our	MS	 group	 suggests	 that	 diffusivity	
abnormalities	may	be	secondary	to	progression,	both	Wallerian	de‐
generation of the axons passing through remote macroscopic brain 
TA B L E  2  Demographic,	clinical	and	radiological	data	for	MS	patients
Whole group Stable group Progression group p‐Valuea
No.	of	patients 46 24 22
Female:male 31:15 17:7 14:8 0.6
Mean	age	at	baseline,	years,	mean	(range) 39.6	(18–61) 39.1	(20–61) 40.2	(18–58) 0.3
Median	time	from	onset	symptom	to	baseline,	
years	(range)
9	(0.7–32.2) 7.6	(1.4–32.2) 12.3	(0.7–31.2) 0.6
Median	disease	duration,	years	(range) 4.2	(0–31.2) 2.3	(0–27.2) 5.9	(0–31.2) 0.1
EDSS,	median	(range)
Baseline 2	(0–7) 1.5	(0–6) 3.0	(0–7) 0.2
Year	1 2	(0–7.5) 1.5	(0–6) 3.5	(0–7.5)
Year	2 2.5	(0–8) 1.5	(0–6) 5.5	(0–8)
Year	3 2	(0–8) 1.5	(0–6) 5.5	(0–8)
Year	4 2	(0–8) 1.5	(0–6) 6.0	(1–8) <0.001
Difference	between	EDSS	over	4	years,	
median	(range)
0.5	(–1.5	to	4) 0	(0.5	to	−1.5) 1.5	(0.5–4)
No.	of	relapses	up	to	three	years	before	baseline,	no.	of	patients	(%)
0 15	(33) 5	(21) 10	(45) 0.07
1–2 24	(52) 14	(58) 10	(45)
3–5 7	(15) 5	(21) 2	(10)
No.	of	relapses	during	the	follow‐up,	no.	of	patients	(%)
0 24	(52.2) 12	(50) 12	(54.5) 1.00
1–2 12	(26.1) 7	(29.2) 5	(22.7)
3–6 10	(21.7) 5	(20.8) 5	(22.7)
Duration	of	treatment	at	baseline,	months,	
median	(range)
18.5	(1–122) 18.5	(1–70) 15.5	(1–122) 0.9
Treatment	at	baseline,	no.	of	patients	(%)b 18	(39) 12	(50) 6	(27) 0.2
Treatment	at	the	end	of	the	follow‐up,	 
no.	of	patients	(%)b
20	(43.4) 12	(50) 8	(36) 0.3
T1 brain lesion load at baseline cm3,	
median	(range)c
1.7	(0.1–28.5) 1	(0.1–28.5) 2.2	(0.1–14.7) 0.1
FLAIR	brain	lesion	load	at	baseline	cm3,	
median	(range)c
5.8	(1–39) 2.8	(1–39) 8.2	(1–33) 0.03
Brain	parenchymal	fraction	at	baseline,	
median	(range)c
0.72	(0.6–0.81) 0.73	(0.64–0.8) 0.68	(0.6–0.81) 0.2
Note.	EDSS,	Expanded	Disability	Status	Scale;	Range	was	defined	as	minimum	and	maximum	values.
aComparison	between	stable	versus	progression	groups,	Mann‐Whitney	U	test	for	median	values,	t	test	for	mean	values,	and	chi‐square	test	for	de‐
scriptive	data;	in	bold,	p	<	0.05.	bFirst‐line	treatment	(beta‐interferon,	glatiramer	acetate).	cValues	calculated	for	42	MS	patients	(23	patients	in	stable	
group,	19	patients	in	progression	group);	there	were	no	significant	differences	regarding	clinical	and	demographic	data	between	group	of	patients	with	
DTI	(n	=	46)	and	the	volumetric	analysis.	
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lesions	(Ge	et	al.,	2004;	Lin	et	al.,	2007)	and	brain	atrophy	due	to	the	
partial	volume	effect	within	voxels	(Roosendaal	et	al.,	2009).
The main observation in our study is the tendency for baseline 
DTI	metrics’	association	 in	 the	CC	with	disability	progression	over	
4 years with the most consistent and stable correlation observed in 
the	CC	splenium.	We	observed	an	 increased	baseline	AD	and	RD,	
indirectly	 representing	 axonal	 integrity	 and	 demyelination,	 which	
is associated with disability progression even after correcting for 
focal lesion volume. This result corroborates observations in a pre‐
vious	study	analyzing	only	FA	maps	where	decreased	FA	in	the	CC	
splenium	in	primary‐progressive	MS	(Bodini	et	al.,	2013)	was	asso‐
ciated	 with	 EDSS	 progression	 over	 5	years;	 however,	 longitudinal	
stability	of	DTI	 indices	has	not	been	analyzed	 in	this	study.	As	we	
investigated	longitudinal	changes	in	both	AD	and	RD	indices,	which	
are	more	specifically	related	to	MS	pathology,	we	can	speculate	that	
inflammatory activity and axonal degeneration are responsible for 
clinical	worsening	in	our	MS	cohort.	Similar	to	our	results,	increased	
RD	in	the	CC	body	has	been	associated	with	motor	impairment	ex‐
pressed	by	the	9‐hole	peg	test	(NHPT)	 in	a	1‐year	follow‐up	study	
with	a	small	number	(n	=	22)	of	patients	with	RRMS	(Kern,	Sarcona,	
TA B L E  3  DTI	indices	at	baseline	and	after	1	year	of	the	follow‐up	in	MS	patients
Relapsing‐onset MS patients, n = 46
DTI metrics
Baseline Year 1 Annual change
p‐ValueaMedian Min Max Median Min Max Median Min Max
Corpus callosum genu
FA 0.78 0.48 0.88 0.81 0.48 0.93 0.03 −0.08 0.14 <0.001
MD 0.80 0.62 1.31 0.82 0.67 1.07 −0.01 −0.34 0.20 0.891
AD 1.73 1.47 2.25 1.84 1.40 2.23 0.10 −0.62 0.43 0.006
RD 0.34 0.17 0.84 0.32 0.12 0.66 −0.04 −0.25 0.14 0.009
Corpus callosum body right
FA 0.56 0.30 0.87 0.68 0.32 0.89 0.06 −0.17 0.30 <0.001
MD 0.83 0.58 1.08 0.81 0.70 1.11 0.01 −0.17 0.24 0.797
AD 1.47 1.07 1.84 1.63 1.13 1.95 0.12 −0.37 0.65 0.003
RD 0.53 0.20 0.92 0.44 0.20 0.75 −0.08 −0.33 0.11 <0.001
Corpus callosum body left
FA 0.58 0.29 0.85 0.68 0.37 0.88 0.10 −0.18 0.31 0.001
MD 0.82 0.67 1.39 0.83 0.68 1.11 0.01 −0.42 0.24 0.589
AD 1.46 1.06 2.08 1.64 1.08 2.00 0.12 −0.37 0.65 0.027
RD 0.52 0.23 1.14 0.45 0.20 0.74 −0.09 −0.40 0.15 <0.001
Corpus callosum splenium
FA 0.79 0.52 0.94 0.82 0.58 0.94 0.02 −0.07 0.20 0.004
MD 0.75 0.56 1.28 0.75 0.58 1.11 −0.02 −0.20 0.21 0.215
AD 1.67 1.23 2.13 1.69 1.42 2.07 0.04 −0.27 0.30 0.157
RD 0.28 0.11 0.86 0.25 0.09 0.69 −0.04 −0.31 0.14 0.003
Internal	capsule	right
FA 0.72 0.62 0.83 0.71 0.55 0.85 0.00 −0.16 0.07 0.304
MD 0.74 0.66 0.79 0.74 0.67 0.83 0.01 −0.05 0.10 0.245
AD 1.46 1.33 1.73 1.45 1.27 1.80 0.00 −0.13 0.14 0.743
RD 0.36 0.24 0.47 0.37 0.23 0.52 0.00 −0.08 0.18 0.345
Internal	capsule	left
FA 0.71 0.47 0.80 0.71 0.49 0.83 0.01 −0.18 0.32 0.814
MD 0.73 0.66 0.87 0.73 0.66 0.84 0.01 −0.06 0.07 0.092
AD 1.46 1.25 1.69 1.48 1.25 1.83 0.03 −0.20 0.45 0.068
RD 0.35 0.26 0.61 0.35 0.25 0.58 0.01 −0.27 0.15 0.566
Note.	Annual	change	is	defined	as	difference	between	median	DTI	value	at	1	year	and	median	DTI	value	at	baseline.
DTI:	 diffusion	 tensor	 imaging;	 FA:	 fractional	 anisotropy;	 MD:	 mean	 diffusivity	 (×10−3 mm2/s);	 axial	 diffusivity	 (×10−3 mm2/s);	 radial	 diffusivity	
(×10−3 mm2/s).
ap‐Value	for	Wilcoxon	test;	in	bold,	p	<	0.05.	
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Montag,	 Giesser,	 &	 Sicotte,	 2011).	 Moreover,	 a	 histogram‐based	
analysis revealed a correlation between whole‐brain diffusivity al‐
terations and disability progression expressed by the MS Functional 
Composite	Scale	over	1	year	(Samann	et	al.,	2012).	The	significance	
of our observation is strengthened by the fact that axonal degener‐
ation,	 represented	here	by	 increased	AD,	 is	mainly	 responsible	 for	
sustained	disability	 in	MS	(Tallantyre	et	al.,	2010).	The	reason	why	
the	most	stable	correlation	between	DTI	and	disability	progression	
was observed in the CC splenium of our study cohort might be re‐
lated to thin axons that are densest in the splenium and their pref‐
erential	 susceptibility	 to	 injury	 in	MS,	as	also	 suggested	by	others	
(Ciccarelli	et	al.,	2003).	As	the	CC	body	is	a	thin	anatomical	structure,	
the partial volume effect from cerebrospinal fluid may influence the 
results	of	DTI	measurements	in	the	region	we	observed.	ROI‐based	
methodology	 is	 sensitive	 to	 the	 change	 in	DTI	 parameters,	 avoids	
postprocessing	 calculation	 errors,	 and	 is	 suitable	 for	 investigating	
well‐defined	brain	structures	such	as	CC	and	IC	(Snook,	Plewes,	&	
Beaulieu,	2007).	Good	reproducibility	of	DTI	measurements	 in	our	
present	and	previous	studies	(Brander	et	al.,	2010;	Hakulinen	et	al.,	
2012;	Kolasa	et	al.,	2015),	along	with	coherent	 fibers	 in	 the	white	
matter	tracts	of	the	IC	and	the	CC,	suggests	that	diffusivity	abnor‐
malities,	as	observed	here,	may	be	related	to	white	matter	pathology	
TA B L E  4  Relationship	of	baseline	DTI	metrics	with	disability	progression	measured	by	EDSS	increase	over	the	4‐year	follow‐up
DTI metrics
Stable group n = 24 Progression group n = 22
p‐Valuea Odds ratio 95% CIMedian Min Max Median Min Max
Corpus callosum genu
FA 0.81 0.52 0.88 0.74 0.48 0.88 0.04 0.00 0.00 0.61
MD 0.80 0.62 1.21 0.83 0.67 1.31 0.06 1.05 1.00 1.10
AD 1.70 1.47 2.07 1.76 1.55 2.25 0.36 1.02 0.98 1.06
RD 0.28 0.17 0.80 0.37 0.17 0.84 0.04 1.05 1.00 1.09
Corpus callosum body right
FA 0.67 0.40 0.87 0.52 0.30 0.77 0.01 0.00 0.00 0.24
MD 0.80 0.58 1.07 0.87 0.69 1.08 0.04 1.08 1.00 1.15
AD 1.51 1.07 1.79 1.39 1.18 1.84 0.25 0.98 0.95 1.01
RD 0.46 0.20 0.73 0.62 0.30 0.92 0.01 1.07 1.02 1.12
Corpus callosum body left
FA 0.66 0.38 0.85 0.53 0.29 0.82 0.07 0.02 0.00 1.37
MD 0.81 0.67 1.32 0.84 0.70 1.39 0.12 1.03 0.99 1.08
AD 1.50 1.19 2.08 1.42 1.06 2.04 0.53 0.99 0.97 1.02
RD 0.46 0.23 0.93 0.58 0.30 1.14 0.04 1.04 1.00 1.08
Corpus callosum splenium
FA 0.82 0.63 0.89 0.76 0.52 0.94 0.04 0.00 0.00 0.76
MD 0.71 0.56 0.95 0.79 0.68 1.28 0.01 1.13 1.03 1.23
AD 1.62 1.23 1.87 1.80 1.50 2.13 0.01 1.08 1.02 1.14
RD 0.25 0.16 0.50 0.35 0.11 0.86 0.02 1.07 1.01 1.14
Internal	capsule	right
FA 0.72 0.62 0.78 0.72 0.62 0.83 0.89 1.01 0.89 1.14
MD 0.72 0.66 0.79 0.75 0.66 0.78 0.14 1.13 0.96 1.33
AD 1.45 1.33 1.61 1.49 1.34 1.73 0.16 1.05 0.98 1.12
RD 0.35 0.29 0.47 0.36 0.24 0.46 0.78 1.02 0.90 1.15
Internal	capsule	left
FA 0.71 0.47 0.80 0.71 0.58 0.80 0.49 1.03 0.94 1.13
MD 0.71 0.66 0.87 0.74 0.66 0.80 0.15 1.12 0.96 1.32
AD 1.42 1.25 1.63 1.48 1.30 1.69 0.05 1.07 1.00 1.15
RD 0.35 0.26 0.61 0.36 0.31 0.48 0.86 0.99 0.90 1.09
Note.	DTI:	diffusion	tensor	 imaging;	FA:	fractional	anisotropy;	MD:	mean	diffusivity	 (×10−3 mm2/s);	axial	diffusivity	 (×10−3 mm2/s);	 radial	diffusivity	
(×10−3 mm2/s);	EDSS:	Expanded	Disability	Status	Scale.
ap‐Value	 for	 logistic	 regression	adjusted	 for	age	and	duration	of	 symptoms	 for	prediction	of	EDSS	progression	over	 the	4‐year	 follow‐up;	 in	bold,	
p	<	0.05.	
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rather than method‐based variability or crossing fibers within a 
voxel	(Wheeler‐Kingshott	&	Cercignani,	2009).
The	1‐year	longitudinal	DTI	analysis	revealed	a	significant	change	
of	DTI	metrics	 in	 the	CC	but	not	 in	 the	 IC.	 In	 this	cohort	with	ac‐
tive	MS	 (Lublin	 et	 al.,	 2014),	 we	 observed	 an	 increase	 instead	 of	
the	expected	decrease	of	FA	in	the	CC.	This	increase	was	driven	by	
increased	AD	and	decreased	RD	in	the	CC	genu	and	the	body	and	
decreased	RD	 in	 the	CC	splenium.	Due	to	a	short	 radiological	 fol‐
low‐up	with	only	two	MRI	examinations,	we	cannot	fully	determine	
the	sustained	changes	in	DTI	parameters.	A	longitudinal	DTI	study	
with	shorter	interval	MRI	examinations	would	be	more	appropriate	
to	 evaluate	 the	 temporal	 changes	 in	diffusivity	 (Tian	et	 al.,	 2012).	
Moreover,	 without	 healthy	 controls	 in	 the	 longitudinal	 analysis,	
we cannot clearly assess pathophysiological processes involved in 
temporal	DTI	changes	observed	here	 in	the	CC.	Similar	 to	our	ob‐
servation,	 serial	 DTI	 study	 using	 tractography	 showed	 significant	
longitudinal	change	in	DTI	metrics	in	the	supratentorial	brain	and	the	
CC	of	the	MS	cohort	with	different	disease	phenotypes	(Harrison	et	
al.,	2011).	However,	such	temporal	DTI	evolution	was	not	observed	
in	a	 recent	ROI‐based	MS	study	 including	natalizumab‐treated	pa‐
tients	(Ontaneda	et	al.,	2017).	In	another	study	in	early	RRMS	with	a	
2‐year	follow‐up,	the	rate	of	change	in	diffusivity	characteristics	as‐
sessed by a histogram‐based whole‐brain analysis did not correlate 
with	 disability	 progression	 expressed	 by	 an	 EDSS	 increase,	which	
confirms	our	results	(Rashid	et	al.,	2008).	Conversely,	the	association	
between	diffusivity	in	the	frontal	NAWM	and	disability	as	measured	
by the MS Functional Composite Scale has been found in primary‐
progressive	MS	 (Schmierer	et	al.,	2004).	Thus,	 inconsistent	 results	
observed	 in	 previous	 studies	 may	 relate	 to	 technical	 differences,	
intrinsic	heterogeneity	of	MS	(Barone	et	al.,	2018)	and	MS	cohorts,	
and different clinical scales used in disability evaluation in MS.
Altogether,	the	results	of	our	longitudinal	study	suggest	that	DTI	
is a sensitive tool in monitoring diffuse abnormalities responsible for 
disability	accumulation,	and	CC	may	be	a	good	target	for	DTI	analy‐
sis.	We	believe	that	an	assessment	of	the	prognostic	value	of	DTI	in	
an MS cohort with variable clinical characteristics such as ours which 
is	typically	encountered	in	everyday	practice	has	practical	value,	as	
suggested	 by	 others	 (Harrison	 et	 al.,	 2011).	Moreover,	 changes	 in	
RD	observed	here	may	play	an	important	role	in	monitoring	immu‐
nomodulatory treatment effects because the attenuation of inflam‐
matory demyelination is the main target of current MS therapies. 
This statement is supported by the results of the study by Fox et 
al.,	where	DTI	abnormalities	indicating	remyelination	have	been	ob‐
served	after	starting	natalizumab	treatment	(Fox	et	al.,	2011).
We	did	 not	 observe	 any	 associations	 in	 the	 IC	 between	 base‐
line	 DTI	 and	 disability	 progression.	 Moreover,	 no	 longitudinal	
changes	 in	DTI	metrics	were	 observed	 in	 the	 IC,	 although	 signifi‐
cant	 differences	 related	 to	DTI	 between	 healthy	 controls	 and	 the	
MS group were already observed. This result indicates that diffu‐
sivity	abnormalities	may	already	exist	 in	 the	 IC,	but	 they	progress	
at	different	rates,	and	image	disability	progression	distinctly	than	in	
the	CC	(Ge	et	al.,	2004).	Our	finding	is	supported	by	studies	where	
no	 correlation	 between	DTI	 indices	 in	 the	 corticospinal	 tract	 and	
disability	progression	expressed	by	an	EDSS	increase	has	been	ob‐
served	(Fritz,	Keller,	Calabresi,	&	Zackowski,	2017;	Lin	et	al.,	2007).	
Conversely,	such	correlation	between	DTI	parameters	and	EDSS	has	
been	 previously	 reported	 in	 cross‐sectional	 studies	 (Daams	 et	 al.,	
2015;	Tovar‐Moll	et	al.,	2015).
Our results corroborate the observed lack of clear‐cut asso‐
ciation	 between	 the	 T1/T2	 brain	 lesion	 load,	 brain	 atrophy,	 and	
disability	progression	expressed	by	EDSS	change	in	other	follow‐
up	studies	for	over	2	years	in	relapsing	MS	(Enzinger	et	al.,	2011;	
Tiberio	et	al.,	2005).	Although	volumetric	measurements	did	not	
clearly	correlate	with	disability	progression	in	our	study,	the	FLAIR	
lesion volume and BPF showed some effect and modified the cor‐
relation	 between	 DTI	 and	 disability	 progression.	 In	 contrast	 to	
our	 results,	 association	 between	 short‐term	 physical	worsening,	
T2	brain	 lesion	 load	 (Gauthier	et	 al.,	2007;	Moodie	et	 al.,	2012),	
and	brain	atrophy	has	been	reported	elsewhere	(Minneboo	et	al.,	
2008;	Samann	et	al.,	2012).	These	discordant	results	suggest	that	
the focal brain lesion load and brain atrophy may have additional 
impact on disability accumulation in relapsing‐onset MS. The lack 
of significant correlation here may be limited by a small number 
of	 cases	 in	 the	 study	cohort,	where	disease	activity	 and	disabil‐
ity progression were variable. Other limitations in our inferences 
may	result	from	the	fairly	gross	nature	of	total	EDSS	in	a	situation	
where there is a need to evaluate subtle changes in motor func‐
tions during a short observation period.
In	conclusion,	our	results	among	others	suggest	that	diffusivity	
abnormalities	 exist	 in	 relapsing‐onset	MS	 patients;	 however,	 their	
dynamic change over time is different with respect to anatomical 
location.	 Additionally,	 diffusivity	 metrics	 in	 the	 normal‐appearing	
CC may be associated with disability accumulation in relapsing‐onset 
MS and suggest the crucial role of the CC in monitoring disease pro‐
gression.	Given	its	high	sensitivity	in	detecting	diffuse	brain	abnor‐
malities,	DTI	 indices	may	serve	as	a	potential	biomarker	of	disease	
progression;	however,	method	standardization	is	needed.	Moreover,	
stability	and	sensitivity	to	underlying	pathology	of	DTI	metrics	have	
to	be	confirmed	in	longitudinal	studies	(Wattjes	et	al.,	2015).	A	com‐
bination of diffusion measures with other findings from conventional 
MRI	may	provide	complementary	information	on	different	types	of	
pathological damage in MS.
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